18th European AIDS Conference

The 18th European AIDS Conference will be organised in London in a hybrid format from 27-30 October 2021. Registration, abstract and clinical cases submission are open. A reduced fee is available for allied professionals, students and community members. Scholarships are available to clinicians/physicians, public health experts, researchers from basic and translational sciences, allied professionals, community members, and other service providers involved in HIV/AIDS. For more information

European Hector Research Award in HIV 2021

The H.W. & J. Hector Foundation, Weinheim, is announcing a prize for European HIV research, which will be awarded for the best scientific achievements in the HIV research area in 2020. Any paper on an HIV-related topic that has been accepted or published in a peer-reviewed journal within the last 24 months (i.e. from October 27, 2019) before the start of the 18th European AIDS Conference can be submitted. More information

WAVE in Ukraine workshop: Save the date!

WAVE is organising its 3rd workshop in Ukraine: “On track to improve the health of women living with HIV” – on 19-20 May and 9-10 June. All the sessions will be streamed in English, Ukrainian and Russian. Click here to learn more about the workshop

Standard of Care for HIV and Coinfections in Europe 2020 report

The EACS Standard of Care meeting report is available in English and Russian on the EACS website. Read the report

EACS Live! Journal Club by YING

The next sessions of the Journal Club will be held on 16 June and 13 July 2021. In June: The impact of Covid-19 on people living with HIV. Chaired by Dr Silvia Nozza. In July: Ageing and antiretroviral therapy in people living with HIV. Chaired by Dr Jose Bernardino. Read more

EACS at ISHEID 2021

YING (EACS Young Investigators) is organising a joint session on HIV & COVID-19 at ISHEID 2021 on 17 May 2021 at 17:30 CEST. ISHEID is taking place virtually from 17-20 May 2021. The symposium will dedicate a privileged place to state-of-the-art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications.
EACS at ECCMID 2021

EACS will co-organise two sessions at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), taking place online from 9-12 July 2021.

**HIV in Europe: getting to zero** (1-hour symposium)
- Innovative approaches to increase uptake of HIV testing
- Strategies for HIV prevention: TasP, PrEP and PEP

**Standards of care in HIV management: where are we?** (Educational workshop)
- European standards of care: where are we?
- HIV and hepatitis audit: final results
- PrEP in Europe: how is implementation and equity of access moving ahead

More information

Pre-ECCMID Days

A series of 5 online educational days will cover hot topics in Clinical Microbiology and Infectious Diseases, and will take place in the 3 months leading up to the 31st ECCMID in July 2021.

The schedule of pre-ECCMID days is as follows:
- 20 April 2021: Pre-ECCMID Day on Vaccines
- 5 May 2021: Pre-ECCMID Day on COVID-19 (Part One)
- 19 May 2021: Pre-ECCMID Day on Diagnostic developments
- 16 June 2021: Pre-ECCMID Day on COVID-19 (Part Two)
- 30 June 2021: Pre-ECCMID Day on Antimicrobial Resistance

More information

Spring European Testing Week

The next Spring European Testing Week will take place on 14-21 May 2021. The aim of the ETW is to unite partner organisations throughout Europe for one week to increase access to testing and promote awareness on the benefits of earlier hepatitis and HIV testing.

More information

39th Annual Meeting of the European Society of Paediatric Infectious Diseases

The 39th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID 2021 Online Meeting) which will take place on 24 – 29 May 2021 entirely online.

Special online registration fees are available.

More information

WHO Global HHS Programmes

Since 1 January 2020, the Sexually Transmitted Infections (STIs) unit has joined the Department of Global HHS Programmes. Hereunder some of their latest publications:


**WHO Human T-lymphotropic virus type 1: technical report:** ([https://www.who.int/publications/i/item/9789240020221](https://www.who.int/publications/i/item/9789240020221) or [https://apps.who.int/iris/handle/10665/339773](https://apps.who.int/iris/handle/10665/339773))

**Public health impact and implications for future actions:** WHO global consultation on the human T-lymphotropic virus type 1, Tokyo, Japan, 13-15 November 2019: ([https://www.who.int/publications/i/item/9789240020023](https://www.who.int/publications/i/item/9789240020023) or [https://apps.who.int/iris/handle/10665/339886](https://apps.who.int/iris/handle/10665/339886))

**Factsheet on HTLV-1:** ([https://www.who.int/news-room/fact-sheets/detail/human-t-lymphotropic-virus-type-1](https://www.who.int/news-room/fact-sheets/detail/human-t-lymphotropic-virus-type-1))

First WEEPI-funded projects being rolled-out

The Western-Eastern European Partnership Initiative on HIV, viral hepatitis and tuberculosis (WEEPI) awarded its first grants in late summer 2020. Seven ‘stage 1’ projects, covering a range of clinical and implementation research topics across the three disease, have been initiated and are being implemented by project teams in four countries in dialogue with WEEPI-affiliated researchers. The projects are at various stages of implementation but all are in progress despite of the ongoing COVID-19 pandemic.

More information
EATG PROMS in HIV Research

EATG did research into the use of PROs for the development of new HIV medicines. Led by the community, the work comprised of a literature review, a survey with people living with HIV taking treatment and stakeholder interviews. The purpose of the work is to describe the current use of PROs in HIV research and development as well as to inform an advocacy agenda to guide the use and development of PROs, highlighting the role of communities living with or affected by HIV. It provides a concrete set of recommendations for people living with HIV, pharmaceutical companies, researchers/clinicians and regulatory bodies/HTAs.

Read more